Welcome to our dedicated page for NeuBase Therapeutics news (Ticker: NBSE), a resource for investors and traders seeking the latest updates and insights on NeuBase Therapeutics stock.
NeuBase Therapeutics, Inc. (NASDAQ: NBSE) is a biotechnology company pioneering a modular antisense technology platform aimed at addressing rare genetic diseases caused by mutant proteins. By leveraging a cohesive and highly precise approach, NeuBase's platform offers significant improvements over traditional gene silencing therapies. Combining the benefits of synthetic methodologies with the accuracy of antisense technologies, NeuBase is positioned to revolutionize treatments for genetic disorders.
The company's primary focus lies in tackling repeat expansion disorders, with initial programs targeting Huntington's disease and myotonic dystrophy, along with dominant genetic disorders. Their innovative platform aims to provide solutions for conditions that currently lack effective treatments.
In recent developments, NeuBase has garnered attention from the investment community. On September 6, 2023, Symetryx Corporation announced its acquisition of 20% of NeuBase's issued and outstanding common stock. Both companies are engaged in strategic discussions to optimize value for NeuBase's shareholders. With a reported cash balance of $14.7 million as of June 30, 2023, NeuBase is also considered an attractive candidate for potential mergers or acquisitions.
NeuBase is actively undergoing a strategic review to explore the best paths forward, including potential mergers, acquisitions, special dividends, or other means to maximize shareholder value. The largest shareholder, Symetryx, is committed to working closely with NeuBase to ensure judicious use of the company's assets during this process.
For more information, investors can contact Dan Ferry, Managing Director at LifeSci Advisors, LLC, at daniel@lifesciadvisors.com, or Todd Branning, Chief Financial Officer at NeuBase, at tbranning@neubasetherapeutics.com. Media inquiries can be directed to media@neubasetherapeutics.com.
NeuBase Therapeutics (Nasdaq: NBSE) reported significant progress in precision genetic medicine, focusing on rare and common diseases. The company has validated its ability to modify the human genome using its platform, Drugging the Genome™, and has nominated a development candidate for myotonic dystrophy type 1 (DM1). They expect to submit an Investigational New Drug (IND) application by Q4 2022. Financially, they reported a net loss of $25.4 million for FY 2021, compared to a loss of $17.4 million the previous year, while cash reserves increased to $52.9 million.
NeuBase Therapeutics (Nasdaq: NBSE) will present a corporate overview at the Jefferies London Healthcare Conference on November 17, 2021, from 8:40 a.m. to 9:15 a.m. GMT. CEO Dietrich A. Stephan, Ph.D., will discuss the company's innovative precision genetic medicines aimed at addressing genetic diseases at their source. NeuBase's therapies focus on silencing disease-causing genetic mutations, with initial applications in neuromuscular, neurological, and oncologic disorders. For more information, visit NeuBase Therapeutics.
NeuBase Therapeutics (Nasdaq: NBSE) has announced that CEO Dietrich A. Stephan, Ph.D., will participate in a fireside chat at the Chardan 5th Annual Genetic Medicines Conference on October 5, 2021, at 11:30 a.m. ET. The event will be accessible via a webcast link or through the company’s website.
NeuBase is focused on developing precision genetic medicines aimed at addressing genetic defects that cause disease, leveraging their proprietary PATrOL™ therapies to target genetic issues at the DNA or RNA level.
NeuBase Therapeutics (Nasdaq: NBSE) announced that its CEO, Dietrich A. Stephan, Ph.D., will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, 2021, at 3:45 p.m. ET. The summit takes place from September 20-23. NeuBase focuses on precision genetic medicines designed to address genetic defects at the base level. Their innovative PATrOL™ therapies aim to resolve various genetic diseases, including neuromuscular, neurological, and oncologic disorders.
NeuBase Therapeutics has appointed Anthony Rossomando, Ph.D., as the new Chief Technology Officer. Dr. Rossomando brings over 25 years of biopharmaceutical experience in developing biologics and peptide processes, crucial for advancing NeuBase's precision genetic medicine platform.
His leadership is expected to enhance the company's capabilities in clinical trials, particularly for the drug candidate targeting myotonic dystrophy, type 1. NeuBase aims to innovate genetic therapies for rare diseases and oncology, leveraging its PATrOL™ platform.
NeuBase Therapeutics announced that CEO Dietrich A. Stephan, Ph.D., will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will take place on September 13 at 7:00 a.m. ET. NeuBase focuses on developing precision genetic medicines aimed at addressing genetic diseases.
Designed to modify gene function, their targeted PATrOL™ therapies are being developed to tackle neuromuscular, neurological, and oncologic disorders. Further details can be accessed through the company's website.
NeuBase Therapeutics (NBSE) reported promising advancements in its genetic medicine platform, with preclinical data highlighting effective delivery of compounds targeting three genetic diseases. The company plans to file an IND for its myotonic dystrophy type 1 (DM1) program in Q4 2022. NeuBase completed a public offering, netting $42.6 million, extending its cash runway into early 2023. However, the company faced increased operating expenses, with a net loss of $8.7 million in Q3 2021, up from $3.8 million the previous year.
NeuBase Therapeutics (Nasdaq: NBSE) announced promising data at its R&D Day regarding its precision genetic medicines pipeline. Key highlights include:
- Functional rescue in myotonic dystrophy type 1 (DM1) after subcutaneous dosing.
- Selective reduction of mutant huntingtin protein in a Huntington’s disease mouse model.
- Launch of a new oncology program targeting the KRAS G12D and G12V mutations.
These advancements showcase the versatility of NeuBase's PATrOL platform, paving the way for clinical trials in DM1 expected in 2022.
NeuBase Therapeutics (Nasdaq: NBSE) will host a virtual R&D day on June 8, 2021, highlighting advancements in myotonic dystrophy type 1, Huntington’s disease, and a new oncology program. The event will feature presentations from management and KOLs. NeuBase's proprietary PATrOL™ platform focuses on developing precision genetic medicines targeting genetic mutations. The event, aimed at investors and analysts, will include a live Q&A session. The company emphasizes its commitment to addressing untreatable diseases with innovative genetic solutions.
NeuBase Therapeutics announced the appointment of Kia Motesharei, Ph.D., as Chief Business and Strategy Officer, effective May 24, 2021. Dr. Motesharei brings over 20 years of experience in business development and strategy within the life sciences sector, having successfully completed over 100 deals. His previous roles include leadership positions at Akcea Therapeutics and EMD Serono. This addition aims to enhance NeuBase’s capacity for partnerships and expand its therapeutic pipeline using its innovative PATrOL™ platform for precision genetic medicines.
FAQ
What is the current stock price of NeuBase Therapeutics (NBSE)?
What is the market cap of NeuBase Therapeutics (NBSE)?
What does NeuBase Therapeutics, Inc. specialize in?
Which diseases is NeuBase currently targeting?
What recent developments have occurred at NeuBase?
What is the financial condition of NeuBase Therapeutics?
Who are the main points of contact for investors and media?
What strategic options is NeuBase exploring?
How does NeuBase’s platform improve upon existing treatments?
Why is NeuBase’s antisense technology considered groundbreaking?
How will the strategic review impact NeuBase’s future?
What role does Symetryx Corporation play in NeuBase’s future?
